December 29, 2023
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
”
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
Multiple prevention tools against respiratory syncytial virus in children became available in the United States this year.
We compiled a list of the most important developments.
New immunizations against RSV became available for children in 2023. Image: Adobe Stock
CDC recommends RSV immunization for infants
In August, the CDC recommended that infants be immunized with a monoclonal antibody against RSV, a month after its approval by the FDA as an intramuscular injection of 50 mg for infants with a body weight less than 5 kg and 100 mg for infants with a body weight of 5 kg or more. Read more.
FDA approves Pfizer’s RSV vaccine to protect infants
Also in August, The FDA approved the first vaccine for pregnant people to protect infants from RSV. The approval came 3 months after FDA advisors voted unanimously that data showed the vaccine (Abrysvo, Pfizer) prevented RSV in infants during their first 6 months after birth when given to pregnant patients in the second or third trimester. Read more.
Q&A: What to know about new RSV immunizations for infants
We spoke with Lori Handy, MD, MSCE, an attending physician in the division of infectious diseases at The Children’s Hospital of Philadelphia and associate director of the hospital’s Vaccine Education Center, about the CDC’s recommendation of RSV immunizations and what they mean for patients and providers. Read more.
VIDEO: US experiencing shortage of RSV immunization
In this video from the Infectious Diseases in Children Symposium, James D. Campbell, MD, MS, professor of pediatrics at the University of Maryland School of Medicine and Center for Vaccine Development and Global Health, notes that RSV is the No. 1 cause of hospitalization among infants in the U.S. and says the rate could be reduced by 80% with widespread use of nirsevimab and the vaccine. Watch here.
Study identifies 16 predictors of infant hospitalization for RSV
Researchers identified 16 predictors of infant hospitalization for RSV and developed a model that clinicians can use to predict an infant’s risk, according to findings published in The Lancet Digital Health. Read more.
Protection from nirsevimab may last longer than an RSV season
The monoclonal antibody nirsevimab, recently approved to prevent RSV-associated lower respiratory disease in newborns and infants, may protect longer than an RSV season, researchers reported at IDWeek. Read more.
Maternal RSV vaccine could significantly reduce clinical visits, costs
Pfizer’s maternal vaccine against RSV could significantly decrease clinical visits among infants and save more than $800 million in overall costs, according to a study presented at IDWeek. Read more.
Q&A: Pediatric RSV prevention tools are a ‘game changer’
John S. Bradley, MD, medical director of infectious diseases at Rady Children’s Hospital-San Diego and a former member of the AMDAC, spoke with Healio about the committees’ deliberations and when physicians can expect to use these prevention tools in practice. Read more.
Published by:
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
”
data-action=”subscribe”>
Subscribe
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Back to Healio
